본문 바로가기
KERD
논문KCI 등재

γ-Secretase in Alzheimer’s disease

Hur Ji-Yeun
생화학분자생물학회 (Korean Society Of Biochemistry And Molecular Biology)|2022.12|Experimental and Molecular Medicine|제54권 |pp. 1-14|DOI 10.1038/s12276-022-00754-8

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류생화학

초록

Alzheimer’s disease (AD) is caused by synaptic and neuronal loss in the brain. One of the characteristic hallmarks of AD is senile plaques containing amyloid β-peptide (Aβ). Aβ is produced from amyloid precursor protein (APP) by sequential proteolytic cleavages by β-secretase and γ-secretase, and the polymerization of Aβ into amyloid plaques is thought to be a key pathogenic event in AD. Since γ-secretase mediates the final cleavage that liberates Aβ, γ-secretase has been widely studied as a potential drug target for the treatment of AD. γ-Secretase is a transmembrane protein complex containing presenilin, nicastrin, Aph-1, and Pen-2, which are sufficient for γ-secretase activity. γ-Secretase cleaves >140 substrates, including APP and Notch. Previously, γ-secretase inhibitors (GSIs) were shown to cause side effects in clinical trials due to the inhibition of Notch signaling. Therefore, more specific regulation or modulation of γ-secretase is needed. In recent years, γ-secretase modulators (GSMs) have been developed. To modulate γ-secretase and to understand its complex biology, finding the binding sites of GSIs and GSMs on γ-secretase as well as identifying transiently binding γ-secretase modulatory proteins have been of great interest. In this review, decades of findings on γ-secretase in AD are discussed.

Abstract

Alzheimer’s disease (AD) is caused by synaptic and neuronal loss in the brain. One of the characteristic hallmarks of AD is senile plaques containing amyloid β-peptide (Aβ). Aβ is produced from amyloid precursor protein (APP) by sequential proteolytic cleavages by β-secretase and γ-secretase, and the polymerization of Aβ into amyloid plaques is thought to be a key pathogenic event in AD. Since γ-secretase mediates the final cleavage that liberates Aβ, γ-secretase has been widely studied as a potential drug target for the treatment of AD. γ-Secretase is a transmembrane protein complex containing presenilin, nicastrin, Aph-1, and Pen-2, which are sufficient for γ-secretase activity. γ-Secretase cleaves >140 substrates, including APP and Notch. Previously, γ-secretase inhibitors (GSIs) were shown to cause side effects in clinical trials due to the inhibition of Notch signaling. Therefore, more specific regulation or modulation of γ-secretase is needed. In recent years, γ-secretase modulators (GSMs) have been developed. To modulate γ-secretase and to understand its complex biology, finding the binding sites of GSIs and GSMs on γ-secretase as well as identifying transiently binding γ-secretase modulatory proteins have been of great interest. In this review, decades of findings on γ-secretase in AD are discussed.

참고문헌 (214)

  1. Terry, R. D., "Dementia of the Alzheimer type", Annu. Rev. Neurosci, 3, pp.77~95 (1980)
  2. St George-Hyslop, P. H., "Piecing together Alzheimer’s", Sci. Am, 283, pp.76~83 (2000)
  3. Perl, D. P., "Neuropathology of Alzheimer’s disease. Mt. Sinai", J. Med, 77, pp.32~42 (2010)
  4. Bateman, R. J., "Clinical and biomarker changes in dominantly inherited Alzheimer’s disease", N. Engl. J. Med, 367, pp.795~804 (2012)
  5. De Strooper, B., "The secretases : enzymes with therapeutic potential in Alzheimer disease", Nat. Rev. Neurol, 6, pp.99~107 (2010)
  6. Sevigny, J., "The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease", Nature, 537, pp.50~56 (2016)
  7. Hardy, J., "The amyloid hypothesis of Alzheimer’s disease : progress and problems on the road to therapeutics", Science, 297, pp.353~356 (2002)
  8. Bettens, K., "Current status on Alzheimer disease molecular genetics : from past, to present, to future", Hum. Mol. Genet, 19, pp.R4~R11 (2010)
  9. Selkoe, D. J., "Alzheimer’s disease : genes, proteins, and therapy", Physiol. Rev, 81, pp.741~766 (2001)
  10. Xu, X., "Gamma-secretase catalyzes sequential cleavages of the AbetaPP transmembrane domain", J. Alzheimers Dis, 16, pp.211~224 (2009)
  11. Gu, Y., "Distinct intramembrane cleavage of the beta-amyloid precursor protein family resembling gamma-secretase-like cleavage of Notch", J. Biol. Chem, 276, pp.35235~35238 (2001)
  12. Sastre, M., "Presenilin-dependent gamma-secretase processing of betaamyloid precursor protein at a site corresponding to the S3 cleavage of Notch", EMBO Rep, 2, pp.835~841 (2001)
  13. Weidemann, A., "A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing", Biochemistry, 41, pp.2825~2835 (2002)
  14. Yu, C., "Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma -secretase processing of the APP and Notch1 transmembrane domains", J. Biol. Chem, 276, pp.43756~43760 (2001)
  15. Qi-Takahara, Y., "Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase", J. Neurosci, 25, pp.436~445 (2005)
  16. Zhao, G., "Identification of a new presenilin-dependent zeta-cleavage site within the transmembrane domain of amyloid precursor protein", J. Biol. Chem, 279, pp.50647~50650 (2004)
  17. Takami, M., "gamma-Secretase : successive tripeptide and tetrapeptide release from the transmembrane domain of beta-carboxyl terminal fragment", J. Neurosci, 29, pp.13042~13052 (2009)
  18. Matsumura, N., "gamma-Secretase associated with lipid rafts : multiple interactive pathways in the stepwise processing of beta-carboxyl-terminal fragment", J. Biol. Chem, 289, pp.5109~5121 (2014)
  19. Olsson, F., "Characterization of intermediate steps in amyloid beta(Abeta)production under near-native conditions", J. Biol. Chem, 289, pp.1540~1550 (2014)
  20. Welander, H., "Abeta43 is more frequent than Abeta40 in amyloid plaque cores from Alzheimer disease brains", J. Neurochem, 110, pp.697~706 (2009)
  21. Portelius, E., "Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease", Mol. Neurodegener, 5, pp.2~ (2010)
  22. Portelius, E., "Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease", Acta Neuropathol, 120, pp.185~193 (2010)
  23. Iwatsubo, T., "Visualization of A beta 42(43)and A beta 40 in senile plaques with end-specific A beta monoclonals : evidence that an initially deposited species is A beta 42(43)", Neuron, 13, pp.45~53 (1994)
  24. Roher, A. E., "beta-Amyloid-(1-42)is a major component of cerebrovascular amyloid deposits : implications for the pathology of Alzheimer disease", Proc. Natl Acad. Sci. USA, 90, pp.10836~10840 (1993)
  25. Roher, A. E., "Morphological and biochemical analyses of amyloid plaque core proteins purified from Alzheimer disease brain tissue", J. Neurochem, 61, pp.1916~1926 (1993)
  26. Wolfe, M. S., "Intramembrane proteolysis: theme and variations", Science, 305, pp.1119~1123 (2004)
  27. Laudon, H., "A nine-transmembrane domain topology for presenilin 1", J. Biol. Chem, 280, pp.35352~35360 (2005)
  28. Levy-Lahad, E., "A familial Alzheimer’s disease locus on chromosome 1", Science, 269, pp.970~973 (1995)
  29. Kimberly, W. T., "Identity and function of gamma-secretase", J. Neurosci. Res, 74, pp.353~360 (2003)
  30. Thinakaran, G., "Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo", Neuron, 17, pp.181~190 (1996)
  31. De Strooper, B., "Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein", Nature, 391, pp.387~390 (1998)
  32. Herreman, A., "Total inactivation of gamma-secretase activity in presenilindeficient embryonic stem cells", Nat. Cell Biol, 2, pp.461~462 (2000)
  33. Zhang, Z., "Presenilins are required for gamma-secretase cleavage of beta-APP and transmembrane cleavage of Notch-1", Nat. Cell Biol, 2, pp.463~465 (2000)
  34. Esler, W. P., "Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1", Nat. Cell Biol, 2, pp.428~434 (2000)
  35. Li, Y. M., "Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1", Nature, 405, pp.689~694 (2000)
  36. Yu, G., "Nicastrin modulates presenilin-mediated notch", glp-1 signal transduction and betaAPP processing, 2000, pp.407, 48~54
  37. Francis, R., "aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation", Dev. Cell, 3, pp.85~97 (2002)
  38. Goutte, C., "APH-1 is a multipass membrane protein essential for the Notch signaling pathway in Caenorhabditis elegans embryos", Proc. Natl Acad. Sci. USA, 99, pp.775~779 (2002)
  39. Leem, J. Y., "Presenilin 1 is required for maturation and cell surface accumulation of nicastrin", J. Biol. Chem, 277, pp.19236~19240 (2002)
  40. Arawaka, S., "The levels of mature glycosylated nicastrin are regulated and correlate with gamma-secretase processing of amyloid beta-precursor protein", J. Neurochem, 83, pp.1065~1071 (2002)
  41. Edbauer, D., "Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation", Proc. Natl Acad. Sci. USA, 99, pp.8666~8671 (2002)
  42. Kimberly, W. T., "Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation", J. Biol. Chem, 277, pp.35113~35117 (2002)
  43. Steiner, H., "PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin", J. Biol. Chem, 277, pp.39062~39065 (2002)
  44. Hebert, S. S., "Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity", Neurobiol. Dis, 17, pp.260~272 (2004)
  45. Donoviel, D. B., "Mice lacking both presenilin genes exhibit early embryonic patterning defects", Genes Dev, 13, pp.2801~2810 (1999)
  46. Herreman, A., "Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency", Proc. Natl Acad. Sci. USA, 96, pp.11872~11877 (1999)
  47. Nguyen, V., "Loss of nicastrin elicits an apoptotic phenotype in mouse embryos", Brain Res, 1086, pp.76~84 (2006)
  48. Serneels, L., "Differential contribution of the three Aph1 genes to gammasecretase activity in vivo", Proc. Natl Acad. Sci. USA, 102, pp.1719~1724 (2005)
  49. Campbell, W. A., "Zebrafish lacking Alzheimer presenilin enhancer 2(Pen-2)demonstrate excessive p53-dependent apoptosis and neuronal loss", J. Neurochem, 96, pp.1423~1440 (2006)
  50. Edbauer, D., "Reconstitution of gamma-secretase activity", Nat. Cell Biol, 5, pp.486~488 (2003)
  51. Hayashi, I., "Selective reconstitution and recovery of functional gammasecretase complex on budded baculovirus particles", J. Biol. Chem, 279, pp.38040~38046 (2004)
  52. Kimberly, W. T., "Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2", Proc. Natl Acad. Sci. USA, 100, pp.6382~6387 (2003)
  53. Takasugi, N., "The role of presenilin cofactors in the gamma-secretase complex", Nature, 422, pp.438~441 (2003)
  54. , aph-1a, and pen-2, "Biochemistry", 2005, 4450~4457
  55. Farmery, M. R., "Partial purification and characterization of gamma-secretase from post-mortem human brain", J. Biol. Chem, 278, pp.24277~24284 (2003)
  56. Capell, A., "Gamma-secretase complex assembly within the early secretory pathway", J. Biol. Chem, 280, pp.6471~6478 (2005)
  57. Beher, D., "In vitro characterization of the presenilin-dependent gammasecretase complex using a novel affinity ligand", Biochemistry, 42, pp.8133~8142 (2003)
  58. Ahn, K., "Activation and intrinsic gamma-secretase activity of presenilin 1", Proc. Natl Acad. Sci. USA, 107, pp.21435~21440 (2010)
  59. Fraering, P. C., "Purification and characterization of the human gammasecretase complex", Biochemistry, 43, pp.9774~9789 (2004)
  60. Escamilla-Ayala, A. A., "Super-resolution microscopy reveals majorly monoand dimeric presenilin1", gamma-secretase at the cell surface, 2020, pp.9, e56679~
  61. Sato, T., "Active gamma-secretase complexes contain only one of each component", J. Biol. Chem, 282, pp.33985~33993 (2007)
  62. Chen, F., "TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity", Nature, 440, pp.1208~1212 (2006)
  63. He, G., "Gamma-secretase activating protein is a therapeutic target for Alzheimer’s disease", Nature, 467, pp.95~98 (2010)
  64. Villa, J. C., "Nontranscriptional role of Hif-1alpha in activation of gammasecretase and notch signaling in breast cancer", Cell Rep, 8, pp.1077~1092 (2014)
  65. Greenfield, J. P., "Endoplasmic reticulum and trans-Golgi network generate distinct populations of Alzheimer beta-amyloid peptides", Proc. Natl Acad. Sci. USA, 96, pp.742~747 (1999)
  66. Small, S. A., "Sorting through the cell biology of Alzheimer’s disease:intracellular pathways to pathogenesis", Neuron, 52, pp.15~31 (2006)
  67. Cataldo, A. M., "Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome", Neurobiol. Aging, 25, pp.1263~1272 (2004)
  68. Takahashi, R. H., "Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology", Am. J. Pathol, 161, pp.1869~1879 (2002)
  69. Sisodia, S. S., "Beta-amyloid precursor protein cleavage by a membrane-bound protease", Proc. Natl Acad. Sci. USA, 89, pp.6075~6079 (1992)
  70. Koo, E. H., "Evidence that production and release of amyloid betaprotein involves the endocytic pathway", J. Biol. Chem, 269, pp.17386~17389 (1994)
  71. Zhang, J., "Subcellular distribution and turnover of presenilins in transfected cells", J. Biol. Chem, 273, pp.12436~12442 (1998)
  72. Lah, J. J., "Endogenous presenilin-1 targets to endocytic rather than biosynthetic compartments", Mol. Cell. Neurosci, 16, pp.111~126 (2000)
  73. Chyung, J. H., "Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage", J. Biol. Chem, 280, pp.4383~4392 (2005)
  74. Frykman, S., "Synaptic and endosomal localization of active gammasecretase in rat brain", PLoS One, 5, pp.e8948~ (2010)
  75. Beher, D., "Proteolytic fragments of Alzheimer’s disease-associated presenilin 1 are present in synaptic organelles and growth cone membranes of rat brain", J. Neurochem, 72, pp.1564~1573 (1999)
  76. Efthimiopoulos, S., "Enrichment of presenilin 1 peptides in neuronal large dense-core and somatodendritic clathrin-coated vesicles", J. Neurochem, 71, pp.2365~2372 (1998)
  77. Lah, J. J., "Light and electron microscopic localization of presenilin-1 in primate brain", J. Neurosci, 17, pp.1971~1980 (1997)
  78. Ribaut-Barassin, C., "Alzheimer’s disease proteins in cerebellar and hippocampal synapses during postnatal development and aging of the rat", Neuroscience, 120, pp.405~423 (2003)
  79. Jutras, I., "Gamma-secretase is a functional component of phagosomes", J. Biol. Chem, 280, pp.36310~36317 (2005)
  80. Pasternak, S. H., "Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane", J. Biol. Chem, 278, pp.26687~26694 (2003)
  81. Chun, J., "Stereoselective synthesis of photoreactive peptidomimetic gamma-secretase inhibitors", J. Org. Chem, 69, pp.7344~7347 (2004)
  82. Hansson, C. A., "Nicastrin, presenilin, APH-1, and PEN-2 form active gammasecretase complexes in mitochondria", J. Biol. Chem, 279, pp.51654~51660 (2004)
  83. Crump, C. J., "Development of sulfonamide photoaffinity inhibitors for probing cellular gamma-secretase", ACS Chem. Neurosci, 7, pp.1166~1173 (2016)
  84. Simons, K., "Functional rafts in cell membranes", Nature, 387, pp.569~572 (1997)
  85. Ehehalt, R., "Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts", J. Cell Biol, 160, pp.113~123 (2003)
  86. Urano, Y., "Association of active gamma-secretase complex with lipid rafts", J. Lipid Res, 46, pp.904~912 (2005)
  87. Vetrivel, K. S., "Spatial segregation of gamma-secretase and substrates in distinct membrane domains", J. Biol. Chem, 280, pp.25892~25900 (2005)
  88. Hattori, C., "BACE1 interacts with lipid raft proteins", J. Neurosci. Res, 84, pp.912~917 (2006)
  89. Wahrle, S., "Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains", Neurobiol. Dis, 9, pp.11~23 (2002)
  90. Hur, J. Y., "Active gamma-secretase is localized to detergent-resistant membranes in human brain", FEBS J, 275, pp.1174~1187 (2008)
  91. Osenkowski, P., "Direct and potent regulation of gamma-secretase by its lipid microenvironment", J. Biol. Chem, 283, pp.22529~22540 (2008)
  92. Thathiah, A., "The orphan G protein-coupled receptor 3 modulates amyloidbeta peptide generation in neurons", Science, 323, pp.946~951 (2009)
  93. Cheng, H., "Mechanisms of disease : new therapeutic strategies for Alzheimer’s disease-targeting APP processing in lipid rafts", Nat. Clin. Pract. Neurol, 3, pp.374~382 (2007)
  94. Rajendran, L., "Subcellular targeting strategies for drug design and delivery", Nat. Rev. Drug Discov, 9, pp.29~42 (2010)
  95. Rajendran, L., "Efficient inhibition of the Alzheimer’s disease beta-secretase by membrane targeting", Science, 320, pp.520~523 (2008)
  96. Fraering, P. C., "Structural and functional determinants of gamma-secretase, an intramembrane protease implicated in Alzheimer’s disease", Curr. Genomics, 8, pp.531~549 (2007)
  97. Kopan, R., "Gamma-secretase : proteasome of the membrane?", Nat. Rev. Mol. Cell Biol, 5, pp.499~504 (2004)
  98. Lazarov, V. K., "Electron microscopic structure of purified, active gammasecretase reveals an aqueous intramembrane chamber and two pores", Proc. Natl Acad. Sci. USA, 103, pp.6889~6894 (2006)
  99. Bai, X. C., "An atomic structure of human gamma-secretase", Nature, 525, pp.212~217 (2015)
  100. Yang, G., "Structural basis of Notch recognition by human gamma-secretase", Nature, 565, pp.192~197 (2019)
  101. Zhou, R., "Recognition of the amyloid precursor protein by human gammasecretase", Science, 363, pp.eaaw0930~ (2019)
  102. Zhou, R., "Macromolecular complex in recognition and proteolysis of amyloid precursor protein in Alzheimer’s disease", Curr. Opin. Struct. Biol, 61, pp.1~8 (2020)
  103. Bolduc, D. M., "Nicastrin functions to sterically hinder gamma-secretase-substrate interactions driven by substrate transmembrane domain", Proc. Natl Acad. Sci. USA, 113, pp.E509~E518 (2016)
  104. Wolfe, M. S., "gamma-Secretase in biology and medicine", Semin. Cell Dev. Biol, 20, pp.219~224 (2009)
  105. Wolfe, M. S., "Substrate recognition and processing by gamma-secretase", Biochim. Biophys. Acta Biomembr, 1862, pp.183016~ (2020)
  106. Guner, G., "The substrate repertoire of gamma-secretase", presenilin, 2020, pp.105, 27~42
  107. Lee, S. H., "APP family regulates neuronal excitability and synaptic plasticity but not neuronal survival", Neuron, 108, pp.676~690 (2020)
  108. Struhl, G., "Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins", Mol. Cell, 6, pp.625~636 (2000)
  109. Griciuc, A., "The role of innate immune genes in Alzheimer’s disease", Curr. Opin. Neurol, 34, pp.228~236 (2021)
  110. Wunderlich, P., "Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage", J. Biol. Chem, 288, pp.33027~33036 (2013)
  111. Bentahir, M., "Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms", J. Neurochem, 96, pp.732~742 (2006)
  112. Yang, G., "Structural basis of gamma-secretase inhibition and modulation by small molecule drugs", Cell, 184, pp.521~533 (2021)
  113. De Strooper, B., "Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease", EMBO Rep, 8, pp.141~146 (2007)
  114. Sun, L., "Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Abeta42 and Abeta40 peptides by gamma-secretase", Proc. Natl Acad. Sci. USA, 114, pp.E476~E485 (2017)
  115. Shearman, M. S., "L-685, 458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity", Biochemistry, 39, pp.8698~8704 (2000)
  116. Esler, W. P., "Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate", Proc. Natl Acad. Sci. USA, 99, pp.2720~2725 (2002)
  117. Dovey, H. F., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain", J. Neurochem, 76, pp.173~181 (2001)
  118. Lai, M. T., "Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities", J. Biol. Chem, 278, pp.22475~22481 (2003)
  119. Nie, P., "gamma-Secretase inhibitors and modulators : mechanistic insights into the function and regulation of gamma-secretase", Semin. Cell Dev. Biol, 105, pp.43~53 (2020)
  120. -S-phenylglycine t-butyl ester reduces A beta levels in vivo in plasma and cerebrospinal fluid in young(plaque-free)and aged(plaque-bearing)Tg2576mice, "J. Pharmacol. Exp. Ther", 2003, 864~871
  121. Wong, G. T., "Chronic treatment with the gamma-secretase inhibitor LY-411, 575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation", J. Biol. Chem, 279, pp.12876~12882 (2004)
  122. Mitani, Y., "Differential effects between gamma-secretase inhibitors and modulators on cognitive function in amyloid precursor protein-transgenic and nontransgenic mice", J. Neurosci, 32, pp.2037~2050 (2012)
  123. Martone, R. L., "Begacestat(GSI-953) : a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer’s disease", J. Pharmacol. Exp. Ther, 331, pp.598~608 (2009)
  124. Doody, R. S., "A phase 3 trial of semagacestat for treatment of Alzheimer’s disease", N. Engl. J. Med, 369, pp.341~350 (2013)
  125. Coric, V., "Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease", Arch. Neurol, 69, pp.1430~1440 (2012)
  126. Siemers, E. R., "Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease", Neurology, 66, pp.602~604 (2006)
  127. Gillman, K. W., "Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor", ACS Med. Chem. Lett, 1, pp.120~124 (2010)
  128. Crump, C. J., "BMS-708, 163 targets presenilin and lacks notch-sparing activity", Biochemistry, 51, pp.7209~7211 (2012)
  129. Zhao, J., "Targeting amyloidogenic processing of APP in Alzheimer’s disease", Front. Mol. Neurosci, 13, pp.137~ (2020)
  130. -L-alaninamide(LY-411575), "J. Pharmacol. Exp. Ther", 2004, 49~55
  131. Lanz, T. A., "Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor, LY-450139", J. Pharmacol. Exp. Ther, 319, pp.924~933 (2006)
  132. Crump, C. J., "Development and mechanism of gammasecretase modulators for Alzheimer’s disease", Biochemistry, 52, pp.3197~3216 (2013)
  133. Weggen, S., "A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity", Nature, 414, pp.212~216 (2001)
  134. Page, R. M., "Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation", J. Biol. Chem, 283, pp.677~683 (2008)
  135. Kretner, B., "Attenuated Abeta42 responses to low potency gammasecretase modulators can be overcome for many pathogenic presenilin mutants by second-generation compounds", J. Biol. Chem, 286, pp.15240~15251 (2011)
  136. Li, T., "Gamma-secretase modulators do not induce Abeta-rebound and accumulation of beta-C-terminal fragment", J. Neurochem, 121, pp.277~286 (2012)
  137. Hawkins, J., "Dynamics of Abeta42 reduction in plasma, CSF and brain of rats treated with the gamma-secretase modulator, GSM-10h", Neurodegener. Dis, 8, pp.455~464 (2011)
  138. Borgegard, T., "First and second generation gamma-secretase modulators(GSMs)modulate amyloid-beta(Abeta)peptide production through different mechanisms", J. Biol. Chem, 287, pp.11810~11819 (2012)
  139. Green, R. C., "Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial", JAMA, 302, pp.2557~2564 (2009)
  140. Yu, Y., "Safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel gamma-secretase modulator, E2212, in healthy human subjects", J. Clin. Pharmacol, 54, pp.528~536 (2014)
  141. Nakano-Ito, K., "E2012-induced cataract and its predictive biomarkers", Toxicol. Sci, 137, pp.249~258 (2014)
  142. Ahn, J. E., "Pharmacokinetic and pharmacodynamic effects of a gammasecretase modulator, PF-06648671, on CSF amyloid-beta peptides in randomized phase I studies", Clin. Pharmacol. Ther, 107, pp.211~220 (2020)
  143. Sivilia, S., "Multi-target action of the novel anti-Alzheimer compound CHF5074 : in vivo study of long term treatment in Tg2576 mice", BMC Neurosci, 14, pp.44~ (2013)
  144. Imbimbo, B. P., "Pharmacokinetics and pharmacodynamics of CHF5074 after short-term administration in healthy subjects", Alzheimer Dis. Assoc. Disord, 27, pp.278~286 (2013)
  145. Mekala, S., "Recent developments of small molecule gamma-secretase modulators for Alzheimer’s disease", RSC Med. Chem, 11, pp.1003~1022 (2020)
  146. Brendel, M., "Amyloid-PET predicts inhibition of de novo plaque formation upon chronic gamma-secretase modulator treatment", Mol. Psychiatry, 20, pp.1179~1187 (2015)
  147. Xu, Y., "Molecular imaging of Alzheimer’s disease-related gamma-secretase in mice and nonhuman primates", J. Exp. Med, 217, pp.e20182266~ (2020)
  148. Rynearson, K. D., "Preclinical validation of a potent gamma-secretase modulator for Alzheimer’s disease prevention", J. Exp. Med, 218, pp.e20202560~ (2021)
  149. Crump, C. J., "Piperidine acetic acid based gamma-secretase modulators directly bind to Presenilin-1", ACS Chem. Neurosci, 2, pp.705~710 (2011)
  150. Pozdnyakov, N., "gamma-Secretase modulator(GSM)photoaffinity probes reveal distinct allosteric binding sites on presenilin", J. Biol. Chem, 288, pp.9710~9720 (2013)
  151. Ohki, Y., "Phenylpiperidine-type gamma-secretase modulators target the transmembrane domain 1 of presenilin 1", EMBO J, 30, pp.4815~4824 (2011)
  152. Chau, D. M., "Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of gamma-secretase", J. Biol. Chem, 287, pp.17288~17296 (2012)
  153. Bateman, R. J., "Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo", Nat. Med, 12, pp.856~861 (2006)
  154. Roberts, B. R., "Biochemically-defined pools of amyloid-beta in sporadic Alzheimer’s disease: correlation with amyloid PET", Brain, 140, pp.1486~1498 (2017)
  155. Holtzman, D. M., "Alzheimer’s disease: the challenge of the second century", Sci. Transl. Med, 3, pp.77sr1~ (2011)
  156. Zhou, S., "CD147 is a regulatory subunit of the gamma-secretase complex in Alzheimer’s disease amyloid beta-peptide production", Proc. Natl Acad. Sci. USA, 102, pp.7499~7504 (2005)
  157. Wakabayashi, T., "Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains", Nat. Cell Biol, 11, pp.1340~1346 (2009)
  158. Hur, J. Y., "The innate immunity protein IFITM3 modulates gamma-secretase in Alzheimer’s disease", Nature, 586, pp.735~740 (2020)
  159. Teranishi, Y., "Affinity pulldown of gamma-secretase and associated proteins from human and rat brain", J. Cell. Mol. Med, 14, pp.2675~2686 (2010)
  160. Muramatsu, T., "Basigin(CD147) : a multifunctional transmembrane protein involved in reproduction, neural function, inflammation and tumor invasion", Histol. Histopathol, 18, pp.981~987 (2003)
  161. Naruhashi, K., "Abnormalities of sensory and memory functions in mice lacking Bsg gene", Biochem. Biophys. Res. Commun, 236, pp.733~737 (1997)
  162. Winkler, E., "Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human gamma-secretase", Biochemistry, 48, pp.1183~1197 (2009)
  163. Vetrivel, K. S., "Evidence that CD147 modulation of beta-amyloid(Abeta)levels is mediated by extracellular degradation of secreted Abeta", J. Biol. Chem, 283, pp.19489~19498 (2008)
  164. Blum, R., "Tmp21 and p24A, two type I proteins enriched in pancreatic microsomal membranes, are members of a protein family involved in vesicular trafficking", J. Biol. Chem, 271, pp.17183~17189 (1996)
  165. Jenne, N., "Oligomeric state and stoichiometry of p24 proteins in the early secretory pathway", J. Biol. Chem, 277, pp.46504~46511 (2002)
  166. Dolcini, V., "TMP21 regulates Abeta production but does not affect caspase-3, p53, and neprilysin", Biochem. Biophys. Res. Commun, 371, pp.69~74 (2008)
  167. Pardossi-Piquard, R., "TMP21 transmembrane domain regulates gammasecretase cleavage", J. Biol. Chem, 284, pp.28634~28641 (2009)
  168. Vetrivel, K. S., "Dual roles of the transmembrane protein p23", TMP21 in the modulation of amyloid precursor protein metabolism, 2007, pp.2, 4~
  169. Hur, J. Y., "Identification of novel gamma-secretase-associated proteins in detergent-resistant membranes from brain", J. Biol. Chem, 287, pp.11991~12005 (2012)
  170. Vetrivel, K. S., "Localization and regional distribution of p23", TMP21 in the brain, 2008, pp.32, 37~49
  171. Zhang, X., "A novel alzheimer-associated SNP in Tmp21 increases amyloidogenesis", Mol. Neurobiol, 55, pp.1862~1870 (2018)
  172. Vetrivel, K. S., "Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes", J. Biol. Chem, 279, pp.44945~44954 (2004)
  173. Levy, S., "Protein-protein interactions in the tetraspanin web", Physiol. (Bethesda), 20, pp.218~224 (2005)
  174. Arduise, C., "Tetraspanins regulate ADAM10-mediated cleavage of TNFalpha and epidermal growth factor", J. Immunol, 181, pp.7002~7013 (2008)
  175. Seipold, L., "The emerging role of tetraspanins in the proteolytic processing of the amyloid precursor protein", Front. Mol. Neurosci, 9, pp.149~ (2016)
  176. Chen, A. C., "Physical and functional interaction between the alpha- and gamma-secretases: a new model of regulated intramembrane proteolysis", J. Cell Biol, 211, pp.1157~1176 (2015)
  177. Ferrer, I., "Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer’s disease", J. Bioenerg. Biomembr, 41, pp.425~431 (2009)
  178. Menard, G., "Cerebral distribution of the B-36VDAC protein in rat, cow and man brain : immunocytochemical study", Cell. Mol. Biol, 40, pp.295~300 (1994)
  179. Ramirez, C. M., "VDAC and ERalpha interaction in caveolae from human cortex is altered in Alzheimer’s disease", Mol. Cell. Neurosci, 42, pp.172~183 (2009)
  180. Sultana, R., "Identification of nitrated proteins in Alzheimer’s disease brain using a redox proteomics approach", Neurobiol. Dis, 22, pp.76~87 (2006)
  181. Rios, J. C., "Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination", J. Neurosci, 20, pp.8354~8364 (2000)
  182. Bai, Y., "The in vivo brain interactome of the amyloid precursor protein", Mol. Cell. Proteom, 7, pp.15~34 (2008)
  183. Bamford, R. A., "The interaction between contactin and amyloid precursor protein and its role in Alzheimer’s disease", Neuroscience, 424, pp.184~202 (2020)
  184. Fan, L. F., "Caspr interaction with Amyloid Precursor Protein reduces amyloid-beta generation in vitro", Neurosci. Lett, 548, pp.255~260 (2013)
  185. Teranishi, Y., "Erlin-2 is associated with active gamma-secretase in brain and affects amyloid beta-peptide production", Biochem. Biophys. Res. Commun, 424, pp.476~481 (2012)
  186. Inoue, M., "Human brain proteins showing neuron-specific interactions with gamma-secretase", FEBS J, 282, pp.2587~2599 (2015)
  187. Smith, S. K., "Identification of syntaxin 1A as a novel binding protein for presenilin-1", Brain Res. Mol. Brain Res, 78, pp.100~107 (2000)
  188. Teranishi, Y., "Proton myo-inositol cotransporter is a novel gamma-secretase associated protein that regulates Abeta production without affecting Notch cleavage", FEBS J, 282, pp.3438~3451 (2015)
  189. Frykman, S., "Identification of two novel synaptic gamma-secretase associated proteins that affect amyloid beta-peptide levels without altering Notch processing", Neurochem. Int, 61, pp.108~118 (2012)
  190. Adolfsson, R., "Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type", Life Sci, 27, pp.1029~1034 (1980)
  191. Schedin-Weiss, S., "Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with gamma-secretase and regulates neuronal amyloid beta-peptide levels", Alzheimers Res. Ther, 9, pp.57~ (2017)
  192. Netzer, W. J., "Gleevec inhibits beta-amyloid production but not Notch cleavage", Proc. Natl Acad. Sci. USA, 100, pp.12444~12449 (2003)
  193. Wong, E., "GSAP modulates gamma-secretase specificity by inducing conformational change in PS1", Proc. Natl Acad. Sci. USA, 116, pp.6385~6390 (2019)
  194. Chu, J., "Pharmacological modulation of GSAP reduces amyloid-beta levels and tau phosphorylation in a mouse model of Alzheimer’s disease with plaques and tangles", J. Alzheimers Dis, 41, pp.729~737 (2014)
  195. Hussain, I., "The role of gamma-secretase activating protein(GSAP)and imatinib in the regulation of gamma-secretase activity and amyloid-beta generation", J. Biol. Chem, 288, pp.2521~2531 (2013)
  196. Olsson, B., "Imatinib treatment and Abeta42 in humans", Alzheimers Dement, 10, pp.S374~S380 (2014)
  197. Satoh, J., "Immunohistochemical characterization of gamma-secretase activating protein expression in Alzheimer’s disease brains", Neuropathol. Appl. Neurobiol, 38, pp.132~141 (2012)
  198. Zhu, M., "Common GSAP promoter variant contributes to Alzheimer’s disease liability", Neurobiol. Aging, 35, pp.2656.e1~2656.e7 (2014)
  199. Lu, T., "Gene regulation and DNA damage in the ageing human brain", Nature, 429, pp.883~891 (2004)
  200. Pendlebury, S. T., "Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia : a systematic review and metaanalysis", Lancet Neurol, 8, pp.1006~1018 (2009)
  201. Jendroska, K., "Ischemic stress induces deposition of amyloid beta immunoreactivity in human brain", Acta Neuropathol, 90, pp.461~466 (1995)
  202. Sun, X., "Regulation of beta-site APP-cleaving enzyme 1 gene expression and its role in Alzheimer’s disease", J. Neurochem, 120, pp.62~70 (2012)
  203. Sharp, F. R., "HIF1 and oxygen sensing in the brain", Nat. Rev. Neurosci, 5, pp.437~448 (2004)
  204. Gustafsson, M. V., "Hypoxia requires notch signaling to maintain the undifferentiated cell state", Dev. Cell, 9, pp.617~628 (2005)
  205. Ni, Y., "Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation", Nat. Med, 12, pp.1390~1396 (2006)
  206. Latapy, C., "beta-Arrestins in the central nervous system", Prog. Mol. Biol. Transl. Sci, 118, pp.267~295 (2013)
  207. Liu, X., "beta-arrestin1 regulates gamma-secretase complex assembly and modulates amyloid-beta pathology", Cell Res, 23, pp.351~365 (2013)
  208. Jung, S., "SERP1 is an assembly regulator of gamma-secretase in metabolic stress conditions", Sci. Signal, 13, pp.eaax8949~ (2020)
  209. Zani, A., "Antiviral protection by IFITM3", Vivo. Curr. Clin. Microbiol. Rep, 5, pp.229~237 (2018)
  210. Everitt, A. R., "IFITM3 restricts the morbidity and mortality associated with influenza", Nature, 484, pp.519~523 (2012)
  211. Ricciarelli, R., "Microarray analysis in Alzheimer’s disease and normal aging", IUBMB Life, 56, pp.349~354 (2004)
  212. Wang, X., "A bridge between the innate immunity system and amyloid-beta production in Alzheimer’s disease", Neurosci. Bull, 37, pp.898~901 (2021)
  213. Yao, A. Y., "Activity of Alzheimer’s gamma-secretase is linked to changes of interferon-induced transmembrane proteins (IFITM) in innate immunity", Mol. Neurodegener, 15, pp.69~ (2020)
  214. Kumar, D. K., "Alzheimer’s disease : the potential therapeutic role of the natural antibiotic amyloid-beta peptide", Neurodegener. Dis. Manag, 6, pp.345~348 (2016)

관련 논문AI추천

Possible roles of amyloid intracellular domain of amyloid precursor protein서유헌, 장근아생화학분자생물학회 · BMB Reports2010 · 제43권 제10호다시 보는 알츠하이머병의 아밀로이드 가설김병수대한생물치료정신의학회 · 생물치료정신의학2014 · 제20권 제3호β-Secretase (BACE1) Purification by Refolding Method and Complex with Hispidin김영준, 박희원, 이보람, 임병우, 임지홍, 홍범수대한화학회 · 대한화학회지2014 · 제58권 제6호Comprehensive MicroRNAome Analysis of the Relationship Between Alzheimer Disease and Cancer in PSEN Double- Knockout Mice김용식, 김태규, 류지원, 임혜인, 함수지, Ya-Ping Tang대한배뇨장애요실금학회 · International Neurourology Journal2018 · 제22권 제4호Effect of 42 amino acid long amyloid-β peptides on Arabidopsis plants김영천, 김지우, 류호진, 안정은, 이정환, 이한결, 정상균한국식물생명공학회 · Journal of Plant Biotechnology2020 · 제47권 제4호Regulation of amyloid precursor protein processing by its KFERQ motif김동호, 박지선, 윤승용생화학분자생물학회 · BMB Reports2016 · 제49권 제6호

이 간행물의 다른 논문 (191건)

Particulate matter promotes cancer metastasis through increased HBEGF expression in macrophages이효진, Park Jun-Young, Lee Moo-Seung, Kim Dae-Soo, Son Mi-Young, Jeong Jinyoung, 박영준, Cho Young-Lai, Lee Seon-Jin, Park Seung-Ho, Yoon Sung-Jin, Choi Song, Jung Jaeeun, Park Young-Ho, Seo Jinho, Lee Jungwoon, Kim Jang-Seongpp. 1-12WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function권호근, 김현석, Yoon Hyun Ju, Kim Gi-Cheon, Oh Sejin, Kim Hakhyun, Kim Yong Keon, Lee Yunji, Kim Min Seo, Kwon Gino, Ok Yeon-Supp. 1-14Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagyFeng Ji, Wu Yong, Zhou Jing, Dai Hui-Qi, Zhu Guang-Zhi, Chen Pan-Hong, Wang Li-Ming, Lu Guang, Liao Xi-Wen, Lu Pei-Zhi, Su Wen-Jing, Hooi Shing Chuan, Ye Xin-Pin, Shen Han-Ming, Peng Tao, Lu Guo-Dongpp. 1-15Hypoxia-induced circRNF13 promotes the progression and glycolysis of pancreatic cancerZhao Qiuyan, Zhu Zhonglin, Xiao Wenqin, Zong Guanzhao, Wang Chuanyang, Jiang Weiliang, Li Kai, Shen Jie, Guo Xingya, Cui Jianhua, Guo Lihong, Wan Rongpp. 1-15The transcriptional profile of keloidal Schwann cellsDireder Martin, Wielscher Matthias, Weiss Tamara, Laggner Maria, Copic Dragan, Klas Katharina, Bormann Daniel, Vorstandlechner Vera, Tschachler Erwin, Jan Ankersmit Hendrik, Mildner Michaelpp. 1-15
원문 보기